PL4021904T3 - Pochodne alfa-d-galaktopiranozydu - Google Patents

Pochodne alfa-d-galaktopiranozydu

Info

Publication number
PL4021904T3
PL4021904T3 PL20775188.4T PL20775188T PL4021904T3 PL 4021904 T3 PL4021904 T3 PL 4021904T3 PL 20775188 T PL20775188 T PL 20775188T PL 4021904 T3 PL4021904 T3 PL 4021904T3
Authority
PL
Poland
Prior art keywords
alpha
galactopyranoside
derivatives
galactopyranoside derivatives
Prior art date
Application number
PL20775188.4T
Other languages
English (en)
Inventor
Martin Bolli
John Gatfield
Corinna Grisostomi
Lubos Remen
Christoph SAGER
Cornelia Zumbrunn
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL4021904T3 publication Critical patent/PL4021904T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL20775188.4T 2019-08-29 2020-08-28 Pochodne alfa-d-galaktopiranozydu PL4021904T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019073063 2019-08-29
PCT/EP2020/074121 WO2021038068A1 (en) 2019-08-29 2020-08-28 Alpha-d-galactopyranoside derivatives

Publications (1)

Publication Number Publication Date
PL4021904T3 true PL4021904T3 (pl) 2024-05-13

Family

ID=72561746

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20775188.4T PL4021904T3 (pl) 2019-08-29 2020-08-28 Pochodne alfa-d-galaktopiranozydu

Country Status (22)

Country Link
US (2) US12319672B2 (pl)
EP (1) EP4021904B1 (pl)
JP (1) JP7612669B2 (pl)
KR (1) KR102824799B1 (pl)
CN (1) CN114585619B (pl)
AU (1) AU2020338816B2 (pl)
BR (1) BR112022003562A2 (pl)
CA (1) CA3148365A1 (pl)
ES (1) ES2972551T3 (pl)
HR (1) HRP20240297T1 (pl)
HU (1) HUE066221T2 (pl)
IL (1) IL290815B2 (pl)
MA (1) MA57000B1 (pl)
MX (1) MX2022002339A (pl)
MY (1) MY207787A (pl)
PH (1) PH12022550436A1 (pl)
PL (1) PL4021904T3 (pl)
RS (1) RS65294B1 (pl)
SA (1) SA522431777B1 (pl)
TW (1) TWI864085B (pl)
UA (1) UA129205C2 (pl)
WO (1) WO2021038068A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2974680T3 (es) 2019-08-09 2024-07-01 Idorsia Pharmaceuticals Ltd Derivados de (2-acetamidil)tio-beta-D-galactopiranósidos
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
UA128909C2 (uk) 2019-08-15 2024-11-20 Ідорсія Фармасьютікалз Лтд 2-гідроксициклоалкан-1-карбамоїльні похідні
AU2021356076A1 (en) 2020-10-06 2023-06-08 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
IL302421A (en) 2020-11-02 2023-06-01 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
JP7844491B2 (ja) * 2021-02-09 2026-04-13 イドルシア・ファーマシューティカルズ・リミテッド ヒドロキシヘテロシクロアルカン-カルバモイル誘導体
EP4301748B1 (en) 2021-03-03 2025-05-07 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
WO2022250976A1 (en) * 2021-05-28 2022-12-01 Glycomimetics, Inc. Galectin-3 inhibiting c-glycoside oximes

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
ES2698101T3 (es) 2012-10-10 2019-01-31 Galectin Therapeutics Inc Compuestos de carbohidrato con restos de galactosa para el tratamiento de la nefropatía diabética y trastornos asociados
EP2914269B1 (en) 2012-10-31 2020-07-29 Galecto Biotech AB Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
EP3250581B1 (en) * 2015-01-30 2021-01-20 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
KR20220129667A (ko) 2015-07-06 2022-09-23 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
US10889610B2 (en) 2016-07-12 2021-01-12 Galecto Biotech Ab Alpha-D-galactoside inhibitors of galectins
CN111032670A (zh) 2017-05-12 2020-04-17 卡莱克汀科学有限责任公司 用于治疗系统性胰岛素抗性病症的化合物及其用途
AU2018265571B2 (en) 2017-05-12 2022-09-29 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
JP2021501180A (ja) 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用
CA3114055A1 (en) 2018-10-15 2020-04-23 Galecto Biotech Ab Prodrug of galactoside inhibitors of galectins
JP2022508720A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤
CA3116515A1 (en) 2018-11-21 2020-05-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2020210308A1 (en) 2019-04-10 2020-10-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US12441754B2 (en) 2019-07-03 2025-10-14 Galecto Biotech Ab Galactoside inhibitor of galectins
US12441755B2 (en) 2019-07-05 2025-10-14 Galecto Biotech Ab Galactoside inhibitor of galectins
ES2974680T3 (es) 2019-08-09 2024-07-01 Idorsia Pharmaceuticals Ltd Derivados de (2-acetamidil)tio-beta-D-galactopiranósidos
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
UA128909C2 (uk) 2019-08-15 2024-11-20 Ідорсія Фармасьютікалз Лтд 2-гідроксициклоалкан-1-карбамоїльні похідні
AU2021356076A1 (en) 2020-10-06 2023-06-08 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
IL302421A (en) 2020-11-02 2023-06-01 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
JP7844491B2 (ja) 2021-02-09 2026-04-13 イドルシア・ファーマシューティカルズ・リミテッド ヒドロキシヘテロシクロアルカン-カルバモイル誘導体
EP4301748B1 (en) 2021-03-03 2025-05-07 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Also Published As

Publication number Publication date
HRP20240297T1 (hr) 2024-05-10
MA57000B1 (fr) 2024-03-29
EP4021904C0 (en) 2024-01-03
CN114585619B (zh) 2024-09-27
RS65294B1 (sr) 2024-04-30
JP7612669B2 (ja) 2025-01-14
IL290815B2 (en) 2025-08-01
IL290815B1 (en) 2025-04-01
EP4021904A1 (en) 2022-07-06
TWI864085B (zh) 2024-12-01
HUE066221T2 (hu) 2024-07-28
AU2020338816B2 (en) 2026-01-08
PH12022550436A1 (en) 2022-12-19
AU2020338816A1 (en) 2022-04-14
SA522431777B1 (ar) 2024-04-30
KR20220053622A (ko) 2022-04-29
CA3148365A1 (en) 2021-03-04
TW202122092A (zh) 2021-06-16
CN114585619A (zh) 2022-06-03
UA129205C2 (uk) 2025-02-05
MY207787A (en) 2025-03-19
US12319672B2 (en) 2025-06-03
US20220281855A1 (en) 2022-09-08
WO2021038068A1 (en) 2021-03-04
IL290815A (en) 2022-04-01
BR112022003562A2 (pt) 2022-05-24
EP4021904B1 (en) 2024-01-03
KR102824799B1 (ko) 2025-06-24
JP2022546029A (ja) 2022-11-02
ES2972551T3 (es) 2024-06-13
US20250257056A1 (en) 2025-08-14
MX2022002339A (es) 2022-04-06

Similar Documents

Publication Publication Date Title
ZA202204675B (en) New methylquinazolinone derivatives
HUE070924T2 (hu) 2-Hidroxicikloalkán-1-karbamoil-származékok
CA189498S (en) Showerbase
IL290815A (en) History of alpha-d-galactopyranoside
PL4077334T3 (pl) Pochodne furoindazolu
CA191618S (en) Floorwasher - nozzle
IL283990A (en) Modified oxopyridine derivatives
CA187781S (en) Banquette
IL290964A (en) A 2-aminoquinazolinone derivative
SI3898637T1 (sl) Derivati rapamicina
SG11202012594RA (en) Spirochromane derivatives
CA189675S (en) Uroflowmeter
LT3796975T (lt) Sulfonilaminobenzamido dariniai
CA190552S (en) Hand-dryer
CA189795S (en) Handshower
GB201919210D0 (en) Dihydro-cyclopenta-isoquinoline derivatives
GB201919213D0 (en) Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
PL3770162T3 (pl) Pochodne dihydrochromenu
CA190386S (en) Beverageware
CA189047S (en) Hammock-tent
CA190385S (en) Beverageware
CA190387S (en) Beverageware
CA190384S (en) Beverageware
ZA202200181B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
CA192228S (en) Hydrogenerator